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Abstract
Background: Breathlessness at rest or on minimal exertion despite optimal treatment of underlying cause(s) is
distressing and prevalent. Opioids can reduce the intensity of chronic refractory breathlessness and an anxiolytic
may be of benefit. This pilot aimed to determine the safety and feasibility of conducting a phase III study on the
intensity of breathlessness by adding regular benzodiazepine to low-dose opioid.
Methods: This is a single site, open label phase II study of the addition of regular clonazepam 0.5mg nocte orally
to KapanolR 10mg (sustained release morphine sulphate) orally mane together with docusate/sennosides in
people with modified Medical Research Council Scale ‡ 2. Breathlessness intensity on day four was the efficacy
outcome. Participants could extend for another 10 days if they achieved > 15% reduction over their own baseline
breathlessness intensity.
Results: Eleven people had trial medication (eight males, median age 78 years (68 to 89); all had COPD; median
Karnofsky 70 (50 to 80); six were on long-term home oxygen. Ten people completed day four. One person
withdrew because of unsteadiness on day four. Five participants reached the 15% reduction, but only three went
on to the extension study, all completing without toxicity.
Conclusion: This study was safe, feasible and there appears to be a group who derive benefits comparable to
titrated opioids. Given the widespread use of benzodiazepines for the symptomatic treatment of chronic re-
fractory breathlessness and its poor evidence base, there is justification for a definitive phase III study.
Introduction
Chronic refractory breathlessness, defined asbreathlessness at rest or on minimal exertion despite
optimal treatment of underlying cause(s), is a distressing and
prevalent symptom across the community1 increasing with
socioeconomic disadvantage2 and as death approaches.3Most
patients attribute their breathlessness to underlying lung
disease.4 It has devastating impacts on patients’ and carers’
quality of life, and is still poorly palliated.3
Regular, low-dose opioids can safely reduce the intensity of
chronic refractory breathlessness.5–7 Opioids are useful agents
to palliate dyspnea, but there is a need to have nonopioid
medications to augment the benefits of opioids or as a
substitute for people who cannot tolerate them or derive no
benefit from them.
Although anxiety is rarely the sole cause of breathlessness,8
it is implicated in the worsening andmaintenance of dyspnea.
A medication with an anxiolytic effect is a logical choice to
explore in prospective clinical studies. Despite widespread
use of benzodiazepines for palliation of chronic refractory
breathlessness in hospice/palliative care, a recent Cochrane
review concluded that there were insufficient data to recom-
mend their use in this setting,9 and even fewer data are
available for the combination of opioids and benzodiaze-
pines.10 The only sizable study was in people in the last hours
or days of life and cannot be applied to people earlier in their
disease trajectories.11
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A long-acting benzodiazepine with pharmacodynamic and
pharmacokinetic data for a range of formulations is the ideal
choice. Clonazepam is the benzodiazepinewith thewidest choice
of formulations (tablet, liquid, injectable) and once daily dosing.
Given the evidence of the efficacy of morphine for the relief
of breathlessness, the aim of this pilot study was to determine
whether it is safe and feasible to conduct a fully powered
phase III study of the addition of clonazepam to regular low-
dose sustained release morphine for the reduction of chronic
refractory breathlessness. The primary outcome in this pilot
study was safety (drowsiness, respiratory depression, wors-
ening cognition). Secondary outcomes were feasibility (re-
cruitment and completion rates, and the logistics for running




This is a single site, open label phase II study of com-
mencing regular clonazepam 0.5mg nocte orally with Kapa-
nolR 10mg (sustained release morphine) mane orally and
docusate and sennosides in people with chronic refractory
breathlessness who are naive to opioids and benzodiazepines.
Refractory breathlessness was where all reversible causes for
breathlessness had been optimally treated.6 The primary
outcome was assessed after four days of therapy. Participants
could choose to extend using the two medications for another
10 days if they achieved > 15% reduction in dyspnea intensity
over their own baseline.
Study participants
The study intended to have complete data for four days on
10 opioid-naı¨ve outpatients who had a palliative diagnosis,
aged 18 years or more who scored ‡ 2 on the modified
Medical Research Council (mMRC) scale,12,13 on stable med-
ications, and a prognosis of > 2 months.
Exclusion criteria included adverse reactions to study
medications; already using study medications at or above
study doses; on amonoamine oxidase inhibitor; poor cognition
(Folstein Mini-mental Status Exam < 24/30);14 Australian-
modified Karnofsky Perfomance Status (AKPS) < 50 at base-
line;15 uncontrolled nausea, vomiting, and/or gastrointestinal
obstruction; estimated glomerular filtration rate < 25 mls/
minute;16 serum alkaline phosphatase, bilirubin, ALT, or AST
> 3x the upper limit of normal; resting respiratory rate < 8; re-
spiratory or cardiac event in the previous week (excluding
upper respiratory tract infections); pregnancy; or unable to give
informed consent or complete diary entries. Participants did
not need to have anxiety to qualify for the study.
Settings
Participants were recruited between October 2011 and
February 2012 from a regional palliative care service that
provides inpatient, consultative, outpatient, and community
care in the public and private sector.
Measurements
Safety. Safety assessments included 100mm visual ana-
logue scales (VAS) for drowsiness, worsening cognition, or
respiratory depression; and monitoring oxygen saturation
(SaO2 ) and end-tidal CO2 at baseline, the end of day 5, and for
those who entered the extension, at the end of day 14. These
measurements used the LifeSense LS1-9R (Nonin Medical
Inc., Delsbo, Sweden).
Feasibility. Feasibility measures were: reasons for non-
recruitment at screening; recruitment and completion rates;
acceptability of patient diaries; and qualitative feedback from
study staff about the logistics of running a fully powered study.
Efficacy. The primary outcome measure to inform the
power calculations of the phase III study was based on
breathlessness right now (morning and evening) on the VAS
on day four. Secondary efficacy outcomes include worst, best,
and average breathlessness in the previous 12 hours (mea-
sured morning and evening).
Data collection and data quality. Demographic and
clinical data were collected by research staff. Patients filled
out twice daily diaries with VAS scores for breathlessness
(now, worst average, and best in the last 12 hours); con-
stipation; and sleep quality.
Sample size. Data on 10 participants was required to
calculate the effect size to inform a power calculation for the
phase III study.
Analysis. Safety, feasibility, and efficacy were summa-
rized descriptively.
Ethics, consent, and trial registration. The study was
approved by the Southern Adelaide Clinical Human Research
and Ethics Committees and registered with the Australian
Clinical Trial Register (ACTRN12610000589088). All partici-
pants provided written informed consent.
Results
Participant flow and study population
Twenty people with dyspnea were screened. The major
reasons for not progressing from screening to consent were:
already on opioids (n = 3), AKPS < 50 (n = 2), out of geographic
region (n = 1), and death (n = 1) (Fig. 1).
Thirteen people consented for the study and 11 had
medication dispensed (8 males, median age 78 years (68
to 89); all had COPD and AKPS median 70 (50 to 80); 6
were on long-term home oxygen). Vital signs included a
median respiratory rate of 19.5 (15 to 27), pulse oximetry
92 (90 to 98), and end-tidal CO2 25 (15 to 38) on room air.
One person withdrew before commencing and one was
hospitalized before beginning the study. One patient
withdrew during the study (day four, continued to feel
unsteady on his feet), and 10 completed the study to the end
of day four.
At baseline, morning VAS ‘breathlessness right now’ had a
median of 68.5mm (range 31–86). Evening VAS ‘breathlessness
right now’ had a median of 63.5 (range 9–75).
For the extension study, five participants achieved a 15%
improvement in ‘breathlessness right now’ over baseline levels,
of whom three went on to the 10-day extension phase, suc-
cessfully completing it.
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Safety
No participants were hospitalized during the course of the
study. No participants were treated for respiratory depres-
sion, and end-tidal CO2 remained stable in all participants. By
day four, two participants reported feeling ‘muchmore sleepy
or drowsy than usual’ and three more that their sleepiness or
drowsiness was ‘more than usual.’ No one reported clouded
cognition or confusion. Only one person withdrew after
commencing, on day four, because of feeling unsteady
walking. Three other people reported this but did not with-
draw. One person reported new difficulties with urinary
stream. Constipation was not symptomatic for participants.
Feasibility
On average, the study recruited one participant per week
from one site from a screening rate of 1.7 participants per
week, and was completed in a 12-week period. Ten out of 11
people who started medication completed to day four.
Efficacy
The median score for morning average dyspnea right now
was 49.5 (6 to 87) with a median reduction of 9mm (23mm
worsening to 80mm improvement) over baseline and in the
evening amedian of 45.4 (2 to 84)with amedian improvement
of 6.5mm (18mm worsening to 64mm improvement) over
baseline. Quality of sleep showed no change over baseline.
Discussion
These data confirm that it is safe and feasible to proceed to a
phase III study using benzodiazepines as an adjunct to opioids in
the symptomatic management of breathlessness given their
currentwidespread use. The question of net effect (accounting for
both symptomatic benefit and any toxicities) will only be an-
swered by an adequately powered study. The median improve-
ment in morning and evening ‘breathlessness right now’ scores are
the same order of magnitude seen in the phase III placebo con-
trolled trials of 20mg daily of sustained release morphine.6
Drowsiness was a symptom for five participants, but this
may or may not be transient. This will need to be evaluated in
future work with longer periods of follow-up.
Five people achieved a 15% reduction over their own
baseline dyspnea scores, but only three of these people elected
to continue to day 14. Although there are no efficacy conclu-
sions given small numbers, this rate is disappointing.
Recruitment rates for this study were excellent; the work of
identifying potential participants and successfully supporting
them to completion was done by a team that is skilled in
palliative care research, especially in people with chronic re-
fractory breathlessness. A more conservative estimate of re-
cruitment will underpin feasibility calculations as this
proceeds to a multisite, phase III study.
What are the other designs that could have been used? The
design could have simply been of clonazepam in opioid and
benzodiazepine naive participants, but ethically this may
have been difficult to defend. The author team has good
quality data about the efficacy of opioids alone in controlled
clinical trials and in prospective dose ranging studies that
could be used to give a historical baseline. There is level-one
evidence demonstrating the ability of opioids to reduce
chronic refractory breathlessness. The adequately powered
randomized controlled trial (RCT) was at 20mg sustained
release morphine per 24 hours. More recent work suggests
benefit for many people at 10mg sustained release morphine
per 24 hours. At the same time, a recent systematic review
FIG. 1. Participant flow. (COPD, chronic obstructive pulmonary disease; AKPS, Australian-modified Karnofsky perfor-
mance status.)
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suggests that benzodiazepines did not have evidence of their
net benefit. As such, setting the dose of morphine at 10mg
(half that of the RCT) with addition of clonazepam was the
compromise made by the authors in designing the study. This
was a design decision, and the investigators felt it would have
been ethically more difficult to justify only using clonazepam
given the recent Cochrane review that suggested there was
not enough evidence to support its use alone.
What does a definitive study look like?
There are several design options. Given evidence that
opioids are effective in chronic refractory dyspnea, option one
would be to titrate opioids to a level of benefit, and then, in a
double blind, randomized study add either low-dose benzo-
diazepine or an additional small increment of opioid (to see if
additional benefit can be gained). Another option would be to
add clonazepam only to people who did not gain net benefit
from opioids. A third option would be to compare daily
benzodiazepines with opioids in a phase III study. The pop-
ulation would be earlier in the disease than the participants at
the end of life in Navigante’s study.11 The primary outcome
will also need to be considered carefully. The current pilot
used the intensity of breathlessness, but the unpleasantness
may arguably also be a reasonable primary outcome.
All participants would complete the Hospital Anxiety and
Depression Scale and anxiety scores will be dichotomized in
stratification at randomization. Any such study would also
need to have an ability to ensure that any early responders
maintained benefit over time and that early toxicity related to
drowsiness disappeared.
Clinical benefit was experienced in the current study but
perhaps at the cost of more toxicity. Carefully collected data
on benefit and harms will be needed prospectively for a lon-
ger period of follow-up.
Acknowledgments
Thanks go to Ms. Debbie Marriott for her expertise in
manuscript formatting and submission, Zac Vandersman for
his work with the data and to all of the participants who gave
their time. The funding for this study was made available from
Basil Thomas Bequest to Repatriation General Hospital, Daw
Park, Australia. The generosity of Foundation Daw Park is
appreciated.
Author Disclosure Statement
No competing financial interests exist.
References
1. Currow DC, Plummer J, Crockett A, Abernethy AP: A com-
munity population survey of prevalence and severity of dys-
pnoea in adults. J Pain Symptom Manage 2009;38(4):533–545.
2. Bowden JA, To T, Abernethy AP, Currow DC: Predictors of
chronic breathlessness: A large population study. BMC
Public Health 2011;11(1):33.
3. Currow DC, Smith J, Davidson PM, Newton PJ, Agar MR,
Abernethy AP: Do the trajectories of dyspnoea differ in
prevalence and intensity by diagnosis at the end of life? A
consecutive cohort study. J Pain Symptom Manage 2010;
39(4):680–690.
4. Johnson M, Bowden J, Abernethy AP, Currow DC: To what
clinical causes do patients attribute their breathlessness? A
population survey. J Palliat Med 2012;15(7):744–750.
5. Jennings AL, Davies AN, Higgins JP, Gibbs JSR, Broadley
KE: A systematic review of the use of opioids in the man-
agement of dyspnea. Thorax 2002;57:939–944.
6. Abernethy AP, Currow DC, Frith P, Fazekas B, McHugh A,
Bui C: Randomised double-blind placebo-controlled cross-
over trial of sustained-release morphine for the management
of refractory dyspnoea. Br Med J 2003;7414(327):523–525.
7. Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P,
Frith P, Briffa M, Johnson MJ, Abernethy AP: Once-daily
opioids for chronic dyspnoea: A dose increment and phar-
macovigilance study. J Pain Symptom Manage 2011;42(3):
388–399.
8. Dudgeon DJ, Lertzman M: Dyspnea in the advanced cancer
patient. J Pain Symptom Manage 1998;16(4):212–219.
9. Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C:
Benzodiazepines for the relief of breathlessness in advanced
malignant and non-malignant diseases in adults. Cochrane
Database Syst Rev 2010(1):CD007354.
10. Clemens KE, Klaschik E: Dyspnoea associated with anxiety:
Symptomatic therapy with opioids in combination with
lorazepam and its effect on ventilation in palliative care
patients. Support Care Cancer 2011;19(12):2027–2033.
11. Navigante AH, Castro MA, Cerchietti LC: Morphine versus
midazolam as upfront therapy to control dyspnea percep-
tion in cancer patients while its underlying cause is sought
or treated. J Pain Symptom Manage 2010;39(5):820–830.
12. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW,
Wedzicha JA: Usefulness of the Medical Research Council
(MRC) dyspnoea scale as a measure of disability in patients
with chronic obstructive pulmonary disease. Thorax 1999;54:
581–586.
13. Anon: Medical Research Council Committee on Aetiology of
Chronic Bronchitis. Standardized questionnaires on respi-
ratory symptoms. Br Med J 1960;2(5213):1665.
14. Folstein MF, Folstein SE, McHugh PR: ‘‘Mini-mental state:’’
A practical method for grading the cognitive state of patients
for the clinician. J Psychiatr Res 1975;12(3):189–198.
15. Abernethy AP, Shelby-James TM, Fazekas BS, Woods D,
Currow DC: The Australian-modified Karnofsky Perfor-
mance Status (AKPS) scale: A revised scale for contempo-
rary palliative care clinical practice. BMC Pall Care. 2005;4:7.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D:
A more accurate method to estimate glomerular filtration
rate from serum creatinine: A new prediction equation.
Modification of Diet in Renal Disease Study Group. Ann
Intern Med 1999;130(6): 461–470.
Address correspondence to:




Daw Park, South Australia 5041
E-mail: david.currow@health.sa.gov.au
744 ALLCROFT ET AL.
Archived at Flinders University: dspace.flinders.edu.au
